We are live on ! Find out more
FDMT icon

4D Molecular Therapeutics
FDMT

64 hedge funds and large institutions have $665M invested in 4D Molecular Therapeutics in 2021 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

75% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 16

23% more funds holding

Funds holding: 52 → 64 (+12)

10% more capital invested

Capital invested by funds: $602M → $665M (+$62.2M)

2.55% more ownership

Funds ownership: 55.09% → 57.64% (+2.6%)

0% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 13

Holders
64
Holders Change
+12
Holders Change %
+23.08%
% of All Funds
1.12%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
28
Increased
13
Reduced
13
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$24M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$18.9M
3
ACM
Aquilo Capital Management
California
+$12.4M
4
LCM
Laurion Capital Management
New York
+$9.67M
5
CC
Casdin Capital
New York
+$9.51M

Top Sellers

Rank Fund Capital Flow
1
SM
SB Management
United Arab Emirates
-$16.4M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$13.6M
3
PA
Perceptive Advisors
New York
-$6.88M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$5.27M
5
O
OrbiMed
New York
-$5.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$3.78M +$3.86M +87,143 New
SCM
27
Soleus Capital Management
Connecticut
$3.73M +$3.81M +86,100 New
WP
28
Woodline Partners
California
$3.72M -$781K -17,624 -17%
Charles Schwab
29
Charles Schwab
California
$2.52M +$2.57M +57,967 New
EHI
30
Eagle Health Investments
Connecticut
$2.17M – – –
PPA
31
Parametric Portfolio Associates
Washington
$1.36M -$132K -2,971 -9%
TD Asset Management
32
TD Asset Management
Ontario, Canada
$1.19M – – –
JP Morgan Chase
33
JP Morgan Chase
New York
$905K +$924K +20,871 New
UBS Group
34
UBS Group
Switzerland
$893K +$912K +20,592 New
Bank of New York Mellon
35
Bank of New York Mellon
New York
$885K +$904K +20,417 New
ACP
36
Acuta Capital Partners
California
$868K – – –
Citadel Advisors
37
Citadel Advisors
Florida
$851K -$1.45M -32,847 -63%
Marshall Wace
38
Marshall Wace
United Kingdom
$814K +$502K +11,324 +152%
N
39
Nuveen
North Carolina
$769K +$785K +17,731 New
Victory Capital Management
40
Victory Capital Management
Texas
$548K +$117K +2,643 +26%
Goldman Sachs
41
Goldman Sachs
New York
$542K -$2.77M -62,492 -83%
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
$509K +$520K +11,737 New
M&T Bank
43
M&T Bank
New York
$455K – – –
Deutsche Bank
44
Deutsche Bank
Germany
$422K +$430K +9,711 New
RA
45
Resolute Advisors
California
$416K +$425K +9,600 New
Bank of America
46
Bank of America
North Carolina
$297K +$303K +6,837 +17,093%
Rockefeller Capital Management
47
Rockefeller Capital Management
New York
$257K +$263K +5,935 New
Capstone Investment Advisors
48
Capstone Investment Advisors
New York
$255K +$260K +5,879 New
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$254K +$259K +5,856 New
CCM
50
CAAS Capital Management
New York
$217K – – –
1
2
3 4

FDMT Hedge Fund Activity: Q1 2021 in Review

64 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q1 2021, worth a combined $665M — up 10% from $602M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new FDMT positions and 16 closed out — a net gain of 12 holders — while 13 added to existing stakes and 13 trimmed.

The largest buyer was BlackRock, adding an estimated $24M. The largest seller was SB Management, cutting an estimated $16.4M.

  • 64 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q1 2021, up from 52 in Q4 2020.
  • Funds reported $665M of 4D Molecular Therapeutics stock for Q1 2021, up 10% quarter-over-quarter.
  • 28 funds opened new 4D Molecular Therapeutics positions in Q1 2021 and 16 closed out, a net change of +12 holders.
  • The largest 4D Molecular Therapeutics buyer in Q1 2021 was BlackRock, an estimated $24M added.
  • The largest 4D Molecular Therapeutics seller in Q1 2021 was SB Management, an estimated $16.4M sold.

Based on aggregated 13F filings for Q1 2021.